Since Leqembi is dosed based on a patient’s weight and offered in single-use vials, about 5.8% of the drug dispensed will be ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
The Therapeutic Goods Administration (TGA) has made the decision not to register lecanemab (LEQEMBI) for the treatment of ...
A simple tweak in available vial sizes of the breakthrough Alzheimer's drug Leqembi could save Medicare hundreds of millions ...
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
New research suggests that Medicare could save up to 74 percent of the money lost from discarded Alzheimer's drug Leqembi or ...
Gene therapy could help obese kids avoid health problems associated with excess weight, including arthritis, a new study ...
Medpage Today on MSN1d
Alzheimer's Drug in Smaller Vial Sizes Could Save Medicare Hundreds of MillionsAn estimated $133 million to $336 million worth of lecanemab may be discarded every year. Adding a 75-mg vial could save ...
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...
An Alzheimer’s treatment from idea to market can take up to 20 years. After a long hiatus, the U.S. Food and Drug ...
Biogen (BIIB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback